Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$9.72 USD

9.72
1,478,038

+0.17 (1.78%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $9.73 +0.01 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $17.98, indicating a -3.75% shift from the previous trading day.

Zacks Equity Research

Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.

Zacks Equity Research

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.

Zacks Equity Research

Implied Volatility Surging for ADMA Biologics Stock Options

by Zacks Equity Research

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

Ekta Bagri headshot

Will Strong Asceniv Sales Drive ADMA Biologics Further?

by Ekta Bagri

ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.

Ekta Bagri headshot

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

by Ekta Bagri

ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.

Zacks Equity Research

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.

Zacks Equity Research

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

by Zacks Equity Research

ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.

Zacks Equity Research

Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XSHQ